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5-FU or capecitabine-based CRT, versus six cycles of 5-FU, leuco vorin and oxaliplatin (FOLFOX) followed by response assessment with CRT reserved for poor responders (<20% response of primary tumour). All patients will then undergo TME with adjuvant FOLFOX. The primary end points of the study are R0 resection rate, local recurrence and DFS. In Europe, the multinational RAPIDO trial (NCT01558921) is randomly assigning 885 patients to a standard arm of long-course CRT, surgery and adjuvant chemo therapy (XELOX) for six cycles versus a short course of radiotherapy and neo adjuvant chemotherapy (XELOX) followed by surgery. Although compliance with neoadjuvant chemotherapy is expected to be superior to adjuvant administration, these trials will not address directly the question of the benefit of adjuvant chemotherapy in the management of rectal cancer.
Overall, the results of the EORTC 22921 study challenges the accepted dogma of routinely using adjuvant chemotherapy after neoadjuvant chemoradiation and surgery for the treatment of rectal cancer; however, how these results can be translated into daily clinical practice is unclear. A distant metasta sis rate of nearly 30% highlights the need for better systemic agents. The decision of administering adjuvant chemotherapy will need to be based on careful consideration of risks according to tumour stage of the patient (both pre and post neoadjuvant treatment), the pathology and biology of the tumour as well as the postoperative performance status and the wishes of the patient. In this context, a nuanced discussion of the potential advantages and drawbacks of adjuvant chemotherapy with patients is mandatory. With the challenges of compliance of adjuvant chemotherapy and conflicting data, new strategies should be pursued including investi gation of neoadjuvant chemotherapy and incorporation of novel systemic agents into innovative treatment paradigms for patients with rectal cancer. After the introduction of monoclonal antithe introduction of monoclonal antibodies for the treatment of indolent lymphomas and chronic lymphocytic leukaemia (CLL) in the 1990s, kinase inhibitors that target B-cell receptor (BCR) signalling are now emerging as the next breakthrough targeted therapy against these types of cancer. Chemo-immunotherapy, which combines anti-CD20 antibodies-such as rituximabwith chemotherapy, is currently the standard therapy for younger patients with these diseases, based on high efficacy and long remissions, especially in low-risk patients. However, elderly patients often cannot tolerate these treatments. Furthermore, chemoimmunotherapy also becomes less effective after disease relapse and in patients with poor prognostic markers, such as disrupted function of the cell-cycle regulator p53 owing to mutations in TP53 or del etions on the short arm of chromosome 17, del (17p). These drawbacks, as well as short-term and longterm toxici ties of chemo-immunotherapy, fostered the develop ment of alternative treatment approaches. Remarkably, kinase inhibitors targeting three different enzymes, the spleen tyrosine kinase (SYK), 1 Bruton's tyrosine kinase (BTK), 2 and the phosphatidylinositol-4,5-bisphosphate 3-kinase δ (PI3Kδ), 3, 4 have all been developed within the past 6-8 years. Specifically, clinical trials evaluating fostamatinib, 1 a SYK inhibitor, and ibrutinib, 2 a BTK inhibitor, have demonstrated high activity of these agents in patients with CLL, indolent B-cell lymphomas, and mantle-cell lymphoma (MCL). Now, two manuscripts by Gopal et al. 3 and Furman et al. 4 highlight the effihighlight the efficacy and safety of idelalisib, a PI3Kδ inhibi-δ inhibiinhibitor, in patients with indolent non-Hodgkin l ymphoma (iNHL) and CLL.
Gopal and colleagues 3 published the results of an open-label phase II trial that accrued 125 patients with relapsed iNHL who had failed to respond to a median of four previous treatments. Patients received idelalisib, as single-agent, continuously at a dose of 150 mg orally twice a day until disease progression or toxicity. The researchers reported an objective response rate of 57%, with over 90% of patients showing a reduction in lymph node sizes. Responses were not affected by disease subgroups, and seemed to be relatively durable (median response duration was 12.5 months). 3 At the same time, Furman et al. 4 published the results of a randomized phase III trial that enrolled 220 patients with CLL, who were randomly assigned to receive rituximab plus either idelalisib (150 mg) or placebo, orally twice a day on a continuous schedule. 4 Significantly higher overall response rates (81% versus 13%) and overall survival (92% versus 80% at 12 months of follow up) favoured the idelalisib arm. 4 The study was, in fact, stopped prematurely by the safety monitoring board owing to the overwhelming efficacy of idelali sib. 4 Particularly encouraging were the response rates in high-risk patients with the chromosomal 17 alteration del (17p), which were similar to those observed in low-risk patients. Both studies established idelalisib as a highly attractive therapy for patients with relapsed iNHL and CLL. The safety profile of idelali sib seems to be relatively benign, with the appearance of few grade 3 or higher adverse effects compared with placebo. These adverse effects include diarrhoea (idelalisib 4%, placebo 0%) and transaminitis (idelali sib 5%, placebo 1%). 4 Diarrhoea could be an on-target effect of idelalisib, given that a mild inflammatory bowel disease was noted in previous experiments with PI3Kδ kinase-mutant mice. 5 Of note, most of these adverse effects could be managed with dose-adjustments or treatment interruptions; however, longer-term observations are needed to establish whether these or other adverse effects could become an obstacle for long-term treatment for a subset of patients.
Idelalisib (also known as CAL-101 or GS-1101) is a potent and selective inhibitor of the p110δ subunit of PI3Ks. PI3Ks are divided into three classes-I, II, and III. Class I kinases contain four isoforms, designated PI3Kα, β, γ, and δ. PI3Ks integrate and transduce signals from various surface mol ecules, such as the BCR, 6 chemokine receptors, and adhesion molecules, thereby regulating key cellular functions, including growth, survival, and migration. 7 The PI3K pathway is commonly activated in human cancers, either by activating mutations of PI3K signalling modules, or by activation of upstream surface receptors. 7 Specifically, mutations in PTEN, PIK3CA (the gene encoding the PI3Kα catalytic subunit p110α), or PIK3C1 (encoding the PI3K p85α regula-α regularegulatory subunit), commonly activate the PI3K pathway in solid tumours. By contrast, malignant B cells from patients with CLL and iNHL do not generally harbour activating PI3K pathway mutations. The activity of PI3K in malignant B cells is maintained through cellular and molecular inter actions with the tumour microenvironment ( Figure 1 ). 8 These interactions occur within secondary lymphatic tissues, and result in the activation of several signalling pathways-such as the PI3K-AKT axis-that are necessary for maintenance and expansion of B cells. 8 BCR signalling is a critical pathway in the pathogenesis of several B-cell malignancies, including CLL. 9 PI3Kδ has an essential, nonredundant role in BCR signalling as demonstrated by the fact that PI3K signalling was able to rescue the survival of mature B cells in BCR-deficient mice. 6 PI3Kδ is the major PI3K isoform in B cells, and its expression is mainly restricted to haematopoietic cells, in which it is involved in B-cell homeostasis and function. Mice with inactivating PI3Kδ mutations have reduced numbers of B1 cells (a subclass of B-cell lympho cytes involved in the humoral immune response) and marginal zone B cells, low immuno globulin levels, poor responses to i mmunization, and defective BCR, CD40 and chemokine receptor signal ling. 5 Correlative studies in patients with CLL demonstrated that treatment with idelali sib thwarts BCR signalling, life support by nurse-like cells, and BCRdependent secretion of the CCL3 chemokine, both in vitro and in vivo. 10 These findings are important for understanding the clinical activity of idelalisib. After beginning therapy with idelalisib, patients with CLL typi cally experience rapid resolution of enlarged lymph nodes, along with a transient surge in blood lymphocyte counts. 3 These effects can be explained by the idelalisib-induced blockade of tissue anchor signals and chemokine receptor signalling, which normally retain CLL cells in lymph glands. 10 Remarkably, treatment with SYK 1 or BTK inhibitors 2 produce similar clinical effects (early, transient lymphocytosis and rapid lymph-node shrinkage) in patients with CLL, which suggests that these BCR-associated kinases have similar roles in CLL cell migration, tissue homing, and survival. On the basis of these observations, the redistribution lymphocytosis can now be considered as a benign target-related clinical outcome rather than an adverse event for this class of inhibitors. 
Although there is much excitement about these new targeted treatments, durability of responses, risk of disease transformation and drug resistance, as well as long-term adverse effects will need to be carefully monitored. The advantages and limitations of idelalisib combination therapy with cytotoxic drugs or antibodies is another issue that remains unanswered and will require further investi gations. Responses to idelalisib in CLL can be accelerated and improved by combination treatment with B celltargeting antibodies, such as rituximab. 4 Moreover, the combination of idelalisib with cytotoxic drugs is expected to increase the remission rates and depth of remissions, but likely at the expense of higher toxicity. Combination trials of idelali sib with various older and newer drugs are ongoing; the results of these studies will further guide us towards the optimal use of PI3K inhibition in B-cell malignancies. 
